| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966199 | Vaccine | 2014 | 7 Pages |
Abstract
BCG revaccination of MTB infected adults is safe, well tolerated, and reactogenicity is similar to that of primary BCG vaccination. Clinical trials of live recombinant BCG or attenuated MTB vaccines may be considered in latently infected adults, with or without INH pretreatment (ClinicalTrials.gov identifier: NCT01119521).
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Mark Hatherill, Hendrik Geldenhuys, Bernadette Pienaar, Sara Suliman, Phalkun Chheng, Sara M. Debanne, Daniel F. Hoft, W. Henry Boom, Willem A. Hanekom, John L. Johnson,